Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen by Reginato, E et al.
 
Photodynamic therapy plus regulatory T-cell depletion produces
immunity against a mouse tumour that expresses a self-antigen
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Reginato, E, P Mroz, H Chung, M Kawakubo, P Wolf, and M R
Hamblin. 2013. “Photodynamic therapy plus regulatory T-cell
depletion produces immunity against a mouse tumour that
expresses a self-antigen.” British Journal of Cancer 109 (8):
2167-2174. doi:10.1038/bjc.2013.580.
http://dx.doi.org/10.1038/bjc.2013.580.
Published Version doi:10.1038/bjc.2013.580
Accessed February 17, 2015 4:20:51 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347643
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAPhotodynamic therapy plus regulatory
T-cell depletion produces immunity against
a mouse tumour that expresses a self-antigen
E Reginato
1,2,6, P Mroz
1,3,4,6, H Chung
1,3,6, M Kawakubo
1, P Wolf
2 and M R Hamblin*,1,3,5
1Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA;
2Department of Dermatology,
Medical University of Graz, Graz 8036, Austria;
3Department of Dermatology, Harvard Medical School, Boston, MA 02114, USA;
4Department of Pathology, Northwestern University, Chicago, IL 60611, USA and
5Harvard-MIT Division of Health Science and
Technology, Boston, MA 02139, USA
Background: Photodynamic therapy (PDT) can lead to development of antigen-specific immune response and PDT-mediated
immunity can be potentiated by T regulatory cell (Treg) depletion. We investigated whether the combination of PDT with
cyclophosphamide (CY) could foster immunity against wild-type tumours expressing self-antigen (gp70).
Methods: Mice with CT26 tumours were treated with PDT alone or in combination with low-dose CY. T regulatory cell numbers
and transforming growth factor-b (TGF-b) levels were measured at several time points after treatment. Mice cured by PDTþCY
were rechallenged with CT26 and monitored for long-term survival.
Results: Photodynamic therapyþCY led to complete tumour regression and long-term survival in 90% of treated mice while the
absolute numbers of Treg decreased after PDTþCY and the TGF-b levels were reduced to a level comparable to naı ¨ve mice.
Sixty-five percent of the mice treated with PDTþCY that survived over 90 days tumour free rejected the rechallenge with the same
tumour when a second dose of CY was administered before rechallenge but not without.
Conclusion: Administration of CY before PDT led to depletion of Treg and potentiated PDT-mediated immunity, leading to
long-term survival and development of memory immunity that was only uncovered by second Treg depletion.
Photodynamic therapy (PDT) is an effective anti-cancer treatment
that involves the administration of a photosensitiser dye (PS),
followed by visible light irradiation of the tumour (Dougherty et al,
1998; Dolmans et al, 2003; Agostinis et al, 2011). The light
activation of the PS triggers a photochemical reaction that
culminates in the production of highly reactive single oxygen
(
1O2) and/or reactive oxygen species that cause immediate cell
damage (Henderson and Dougherty, 1992). Additionally, PDT
leads to destruction of tumour vessels and the induction of acute
inflammatory responses (Jalili et al, 2004; Castano et al, 2006).
Photodynamic therapy has been approved as a treatment modality
by US Food and Drug Administration for the use in oesophageal
and bronchial cancer and also for pre-invasive and invasive
malignant conditions of oral cavity, stomach, bladder, breast and
skin (actinic keratosis) (Pass, 1993; Dougherty, 2002; Huang, 2005;
Agostinis et al, 2011). One interesting aspect of PDT is its ability to
stimulate a systemic immune response against a locally treated
tumour (Castano et al, 2006). In fact, PDT has been shown to
effectively stimulate both the innate and the adaptive immune
systems of the host (Korbelik, 1996; Dougherty et al, 1998;
Korbelik et al, 2005) by triggering the release of various pro-
inflammatory and acute-phase response mediators (Cecic and
Korbelik, 2002; Korbelik et al, 2008; Garg et al, 2011) that lead to
infiltration of the treated site by a large number of neutrophils,
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Cecic et al, 2006; Gollnick et al, 2006).
It has been suggested that tumour development and
progression may be strongly dependent on the immune system
ability to recognise and destroy malignant cells. However,
several lines of evidence suggest that tumours can escape
immune surveillance by decreasing or losing the expression of
tumour antigens or MHC molecules or by inducing highly
immunosuppressive tumour microenvironment by producing
high levels of immunosuppressive cytokines like transforming
growth factor-b (TGF-b) or IL-10 that in turn promote the
development and proliferation of CD4
þCD25
þFoxP3
þ T
regulatory cells (Tregs) and immature dendritic cells (Curiel
et al, 2004). In healthy individuals, Treg has an important role
in maintaining immune homeostasis and tolerance to self-
antigens, and preventing autoimmune diseases (Woo et al,
2001; Golgher et al, 2002; Sakaguchi et al, 2008); while in
cancer patients the fine balance between Treg and effector T
cells is usually distorted and the unrestrained expansion of
Treg may foster cancer progression (Valzasina et al, 2006). This
immunosuppressive tumour environment presents therefore a
therapeutic challenge, but several reports have indicated that
the depletion of Treg in vivo facilitates tumour eradication and
enhances anti-tumour immunity (Shimizu et al, 1999; Golgher
et al, 2002; Tanaka et al, 2002). More recently, the anti-Treg
antibody, ipilimumab that targets CTLA-4 has been
approved by the FDA and the European Medicine Agency
(EMEA) for the treatment of metastatic malignant melanoma
(Hodi et al, 2010).
In this report, we further investigate a potential relationship
between PDT and Treg. There are limited reports that suggest
that PDT on its own may have some immunosuppressive
effects (Mroz and Hamblin, 2011), but its effects on Treg have
not been thoroughly elucidated. We have previously shown
that if Treg is depleted by low-dose cyclophosphamide (CY,
50mgkg
 1) (a traditional cytotoxic cancer drug that at low
doses selectively depletes Tregs in mice; Lutsiak et al, 2005),
the PDT-induced anti-tumour immune responses are poten-
tiated and a memory immunity is generated against metastatic
J774 tumours (Castano et al, 2008). This effect was not
observed when PDT was combined with high-dose CY
(150mgkg
 1). We also showed (Mroz et al, 2010) that PDT
of CT26 tumours expressing a model tumour antigen (Chen
et al, 1996) led to long-term survival and spontaneous
regression of remote, untreated antigen-positive tumours.
However, PDT of CT26 wild-type tumours led only to local
regression followed by recurrence, despite the fact that several
reports showed that CT26 tumours also express tumour
antigens, in particular a single peptide epitope known as AH-
1, a non-mutated nonamer derived from the envelope protein
(gp70) of an endogeneous ecotropic murine leukaemia
provirus (Huang et al, 1996). Recently, a paper by
McWilliams et al (2008) described the expression of gp70
mRNA in several tissues of BALB/c mice resulting in
immunologic tolerance that affects anti-tumour immunity. In
view of these reports, it is possible that gp70 antigen in CT26
tumours behaves like a self-antigen and can serve as a model of
cancer shared/auto-antigen.
In this report, we hypothesised that combination of 50mgkg
 1
CY leading to previously shown depletion of Treg with
PDT may result in uncovering a PDT-mediated immune
response to tumours expressing a model shared tumour antigen
gp70.
We also investigated whether the potentiation of PDT by CY is
related to the levels of Treg in the spleen and lymph nodes (LNs)
and/or to the secretion of the immunosuppressive cytokine, TGF-
b, in the serum.
MATERIALS AND METHODS
Cell lines. CT26 wild-type cell line (ATCC, Manassas, VA, USA)
were cultured in RPMI medium with L-glutamine and NaHCO3
supplemented with 10% heat inactivated fetal bovine serum,
penicillin (100Uml
 1) and streptomycin (100mgml
 1) (all from
Sigma, St Louis, MO, USA) at 371Ci n5 %C O 2 in 75cm
2 flasks
(Falcon; Invitrogen, Carlsbad, CA, USA).
Mouse tumour model. BALB/c mice (6–8 weeks old) were
purchased from Charles River Laboratories (Boston, MA, USA).
All experiments were carried out according to a protocol approved
by the Subcommittee on Research Animal Care (IACUC) at MGH
and were in accord with NIH guidelines. Mice were inoculated
with 350000 cells subcutaneously into the depilated right thigh.
Two orthogonal dimensions (a and b) of the tumour were
measured 2–3 times a week with vernier calipers. Tumour volumes
were calculated as follows, volume¼4p/3 [(aþb)/4]
3. When
tumours reached a diameter of 5–7mm (10 days after inoculation)
PDT was performed.
Photosensitiser and light source. Liposomal benzoporphyrin
derivative mono acid ring A (BPD) was a generous gift from
QLT Inc. (Vancouver, BC, Canada) and was prepared by diluting
the powder to a concentration of 0.3mgml
 1 in sterile 5%
dextrose. A 1W 690-nm diode laser (B&W Tek Inc., Newark, DE,
USA) was coupled into a 0.8-mm diameter fibre.
PDT and CY treatment. Tumour-bearing mice were anaesthe-
tised with intraperitoneal (i.p.) injection of 87.5mgkg
 1 of
ketamine and 12.5mgkg
 1 of xylazine and BPD (1mgkg
 1 in
5% dextrose solution) was administered i.v. via the supraocular
plexus. Control mice received 5% dextrose only. Fifteen minutes
after BPD injection, illumination was performed. We measured the
light power with a power meter (THORLABS GmbH, Dachau,
Germany; PM 100D) and calculated the correct distance between
the optic fibre and the tumour, to use 100mWcm
 2 fluence rate
in the exposed area. A total fluence of 120Jcm
 2 was delivered at
a fluence rate of 100mWcm
 2. The mice were killed when any of
the tumour diameters exceeded 1.5cm or tumour volume reached
1500mm
3. In certain groups of mice, 50mg of CY was admini-
stered via i.p. injection 2 days before PDT.
Surgical operation. When tumours reached 5–7mm in diameter
tumour was excised under general anaesthesia with i.p. injection of
87.5mgkg
 1 of ketamine and 12.5mgkg
 1 of xylazine. After the
surgical operation, mouse was killed at five different time points
(0, 1, 4, 10 and 14 days).
Rechallenge. Mice surviving 90 days after PDT were subsequently
rechallenged with 350000 cells of CT26 in the left thigh and
monitored for another 60 days. Naı ¨ve control mice were inoculated
with the same sample of cells as a control for tumorigenicity.
A group of mice received 50mgkg
 1 of CY via i.p. injection 2 days
before rechallenge
Flow cytometry analysis of Treg. There were 18 mice per group
killed in groups of 3 mice per time point. Spleen and inguinal LNs
were harvested at six different time points ( 2 days, 0h, 1, 4, 10
and 14 days). Both organs were homogenised separately by gently
pressing them through the 70-mm cell strainer, using a syringe
plunger to make single-cell suspensions. Cells were counted by
trypan blue exclusion on a haemocytometer after red blood cell
lysis. In all, 1 10
6 of either splenocytes or lymphocytes from LNs
was washed and resuspended in staining buffer (eBioscience, San
Diego, CA, USA). The cells were incubated with rat anti-mouse
CD16/CD32 (FcRgIII/II) mAb (eBioscience) to minimise the
binding to the Fc receptor by the staining antibodies.
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primary antibodies against the markers CD4 (RM4-5, FITC
conjugated; eBioscience) and CD25 (PC61.5, phycoerythrin
conjugated; eBioscience). After washing and fixation/permeabilisa-
tion, the cells were incubated with primary conjugated anti-Foxp3
antibody (FJK-16s). An FACSAria flow cytometer was used for
data acquisition (Becton Dickinson, San Antonio, TX, USA). In all,
50000 events were counted in the case of splenocytes and 20000
for the lymphocytes. All data were analysed with either FACSAria
or FlowJo (TreeStar, Ashland, OR, UAS) software. Isotype controls
were used to set proper regional gates.
ELISA for TGF-b. Blood samples were drawn from the aorta and
were centrifuged at 6000r.p.m. for 20min to extract serum. All
samples of sera were stored in the  801C degree freezer until
ELISA was performed. ELISA for TGF-b (R&D Systems,
Minneapolis, MN, USA; DuoSet) was performed according to the
manufacturer’s instructions. Briefly, 20ml of serum was incubated
with 20ml of 2.5N acetic acid/10M urea for 10min to activate
TGF-b. After 10min of incubation, the samples were neutralised
by adding 20ml of 2.7N NaOH/1M HEPES (at this stage the serum
is diluted 1:3). After 10min of incubation, 30ml of diluted samples
was 15-fold further diluted with Reagent diluents (1.4% bovine
serum albumin, 0.05% Tween-20 in PBS) and used for the assay.
RT–PCR. Total RNA was extracted from cultured cancer cells
using the RNeasy Plus Mini kit (Qiagen, Gaithersburg, MD, USA)
and reversely transcribed by using the Seniscript RT kit (Qiagen).
Primers for specific murine TGF-b (sense, TGCTTCAGCTCCA
CAGAGAA: antisense, TGGTTGTAGAGGGCAAGGAC) (Sieber
et al, 2011) and murine gp70 (sense, AAGGTCCAGCGTTCT
CAAAAC; antisense, AGGTGGCGTTAGCTGTTTGT) (Abe et al,
2012) were used with 2mg of sample cDNA and amplified with Taq
polymerase (Qiagen) using Thermal Cycler (GeneAmp PCR
system 9700; Applied Biosystems, Woburn, MA, USA).
Statistics. Comparisons of Treg and TGF-b values were done by
one-way ANOVA followed by Tukey post hoc test. Survival
analysis was carried out by plotting in the ordinate the percentage
of surviving mice out of the total number of mice per treatment
group. According to the protocol, when the tumours reached
1500mm
3, the mice were euthanised and therefore counted as
dead. In the statistical analysis, we used the log-rank test and in all
cases the significance level was set at Po0.05.
RESULTS
The combination of 50 mgkg
 1 CY with PDT leads to tumour
eradication and survival advantage. We employed a vascular
BPD-PDT regimen delivered alone, or in combination with CY
(50mgkg
 1). Cyclophosphamide was administered on day 8 after
CT26 tumour inoculation and PDT performed at day 10
(Figure 1). Photodynamic therapy produced a good local response
in CT26 tumours as manifested by development of oedema
followed by a circumscribed black eschar and a marked reduction
in tumour size lasting until day 18 (Figure 2A). However, local
tumour regrowth occurred in all treated mice and the median
survival time of the PDT-treated mice was 29 days vs 25 days for
control untreated CT26 (Figure 2B).
When mice were treated with the combination of BPD-PDT and
CY, the outcome was completely different from that seen in mice
treated with PDT alone. Figure 2A shows that PDT and CY
together led to greater local oedema compared with PDT alone
followed by tumour regression in 9 out of 10 mice with all 9 mice
surviving tumour free for 490 days (Figure 2B). Mice treated with
CY alone showed some tumour growth delay (Figure 2A), but the
survival of this group of mice was not significantly different from
control untreated mice, or treated with PDT alone (Figure 2B).
These results taken together suggest that PDT combined with
50mgkg
 1 of CY led to a dramatic improvement in long-term
survival when compared with either treatment alone.
CY combined with PDT abrogates the increase in Treg induced
by PDT alone. To elucidate the immunostimulatory/immuno-
suppressive effects of PDT alone, and combined with 50mgkg
 1
of CY, we examined the absolute number of CD4
þCD25
þ
Foxp3
þ Tregs in both spleen and LNs at different time points after
PDT (0, 1, 4, 10 and 14 days). We included five groups of mice in
the study: (A) tumour-free mice, that received PDT (PDT no
cancer); (B) mice inoculated with cancer and treated with PDT
(PDT cancer); (C) tumour-bearing mice that received injection
of 5% dextrose and laser therapy alone (sham PDT cancer);
(D) tumour-bearing mice that were treated with PDT and CY
combined (PDTþCY cancer) and (E) tumour-bearing mice
injected with CY alone (CY cancer). We also measured the
numbers of Tregs in naı ¨ve mice (i.e., mice without cancer that had
not received any kind of treatment) and the values obtained were
0.152±0.011 10
6 (n¼3) in the spleen and 0.199±0.020 10
6
(n¼3) in the LNs.
The absolute numbers of Treg measured from spleen and LNs in
the five groups are depicted in Figure 3A and B, respectively, and
the P-values obtained from statistical analyses are displayed in
Table 1 for spleen and Table 2 for LNs.
We found that PDT alone led to a significant increase in
CD4
þCD25
þFoxp3
þ Treg between day 0 and day 4 after
treatment in the spleen and also in the LNs. At later time points,
the numbers of Treg in both organs dropped back to values
comparable to the naive mice. The ‘PDT no cancer’ group showed
that Treg was highly, but not significantly increased in the spleen at
day 4, and significantly increased in the LNs at day 4.
The ‘sham PDT cancer’ group displayed a gradual and
significant raise of Treg in both the spleen (Figure 3A) and the
LNs (Figure 3B), to levels much higher than in PDT-treated mice
(at 14 days, Po0.001 in both spleen and LNs) coinciding for the
progression and increase in size of tumour. In the ‘CY alone’
group, the absolute numbers of Treg decreased between  2 days
and 1 day after PDT in both spleen (Figure 3A) and LNs
(Figure 3B), confirming that CY is effectively depleting Tregs.
Then, similarly to the sham PDT cancer group, Tregs increased
steadily between 1 day and 14 days, in both organs, to levels higher
than in naı ¨ve mice (at 14 days Po0.001 in both spleen and LNs).
When CY was combined with PDT, Tregs decreased in both
spleen and LNs reaching a minimum at 0 day and then remained
PDT AND CY ADMINISTRATION
BPD injection
Tumour inoculation
CT26 cells
RECHALLENGE OF MICE CURED BY PDT + CY (OR NAIVE)
0
98 100 160 Days after tumour
10
±CY
±CY
PDT
8
Laser 690 nm
Control
no RNA
gp70
Days after tumour
Sample
1
Sample
2
15′
0day 1day 4days 10days 14days ANALYSIS OF Tregs
TREATMENTS
TREATMENTS Tumour rechallenge
CT26 cells
Figure 1. (A) Experimental design scheme of in vivo PDT, CY
administration and tumour rechallenge. (B) RT–PCR expression of
gp70 in CT26 cells.
PDT plus cyclophosphamide of CT26 mouse tumours BRITISH JOURNAL OF CANCER
www.bjcancer.com|DOI:10.1038/bjc.2013.580 2169within the ‘naı ¨ve’ range during PDT and all the time points after
the treatment
These results indicate that tumour alone as well as PDT alone
may lead to an increase in Treg population, and that this
unfavourable effect can be abrogated by administration of CY
before PDT.
PDT combined with CY, but not PDT alone, decreases TGF-b to
a baseline level. Since TGF-b is the major cytokine involved in
Treg-mediated immunosuppression as well as it can lead to an
increase in numbers of Treg, we measured the level of TGF-b in
the serum of mice treated with PDT, PDTþCY or mice with
tumour that was surgically removed. We also measured the level of
TGF-b in naı ¨ve mice and the value was 1412.41±93.31pgml
 1
(n¼3). Our results demonstrate that PDT alone led to moderate
elevation of TGF-b levels in serum as compared with naı ¨ve mice
while the combination of PDTþCY led to a significant decrease in
TGF-b levels at day 1 (Figure 4B; Table 3) and the TGF-b levels in
this group remained low throughout the entire period of the
experiment.
To determine to which extent PDT is responsible for TGF-b
secretion and not the tumour itself, we analysed the serum samples
from mice whose tumours were surgically removed (Surgery
cancer). Upon tumour resection, TGF-b decreased gradually and
significantly (at 4 days Po0.01 and 14 days Po0.001 compared
with 0 day), becoming comparable to the levels from naı ¨ve mice at
14 days after treatment.
Treg suppresses the reactivation of the long-term anti-tumour
memory immunity generated by PDT plus CY. To investigate
whether the combination of PDT and CY induces the formation of
memory immunity, mice that were treated by PDTþCY and
remained tumour free for 90 days were subsequently rechallenged
with the same tumour cells (CT26). Naı ¨ve mice were used as a
control. As shown in Figure 5, the tumours were not rejected in the
PDTþCY cured mice (CT26 WT CY cured rechall) and the
median survival time of PDTþCY treated rechallenged mice was
18 days vs 25 days for nao ˜ve mice. When the rechallenge was
preceded by administration of 50mgkg
 1 of CY, 65% of mice
rejected the rechallenge (CT26 WT CY cured CY rechall) and
remained tumour free for another 60 days of observation. When
CY was given in naı ¨ve mice before tumour inoculation, all tumours
progressed and all the mice were killed due to the tumour burden
(median survival time¼22 days). These data show that PDTþCY
leads to development of memory immunity T cells, that is however
suppressed by the Treg. The administration of CY to deplete Treg
again at the time of rechallenge abrogated the immunosuppressive
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Figure 3. Quantification of Tregs in the spleens and lymph nodes.
Absolute numbers of CD4
þCD25
þFoxp3
þ Tregs from spleens (A) and
lymph nodes (B) extracted from the mouse groups: PDT no cancer, PDT
cancer, sham PDT cancer, PDTþCY cancer and CY cancer. Bars are
s.e.m. Statistical comparisons are shown in Table 1 (spleen) and Table 2
(lymph nodes). Significance was determined by one-way ANOVA and
Tukey post hoc correction.
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to rechallenge rejection in 65% of cases,
DISCUSSION
In a previous work, we showed that PDT combined with low-dose
CY produced a dramatic improvement in survival and formation
of anti-tumour immunity manifested by rejection of tumour
rechallenge in mice bearing the highly metastatic J774 tumour
(Castano et al, 2008). In the present study, we investigated whether
this potentiating effect of CY on PDT-induced immunity could
also be extended to other mouse tumour models. Therefore, we
employed CT26 colon adenocarcinoma and found that the
combination of PDT with low-dose CY produced a dramatic
improvement in long-term survival, whereas treatment with PDT
or 50mgkg
 1 of CY alone did not lead to a significant survival
advantage.
The CY administration has been suggested to have a specific effect
in depleting the Treg (Awwad and North, 1988; Awwad and North,
1989; Ghiringhelli et al, 2004) and has been used in several studies to
induce tumour regression and increase the immunological responses
against cancer, that could otherwise be suppressed by Treg.
To our knowledge, the effect of PDT on Treg has not been
described so far. Here, we show for the first time that PDT led to a
significant increase of Treg in the first few days post treatment in
both spleen and LNs, reaching a peak at 4 days after PDT. In the
following days, Treg numbers reduced back to levels comparable to
those before the treatment.
Interestingly, this transient PDT effect on Treg levels was not
related to the presence of cancer cells as PDT had the same effect in
tumour-free mice. These results corroborate the hypothesis that
PDT does not act only as a local therapy, capable of destroying
tumours at the site of light exposure, but PDT may also have
profound systemic immunological effects.
Several pre-clinical and clinical studies have shown that PDT is
capable to influence the adaptive arm of the immune system in
many different ways; some regimens leads to potentiation of
adaptive immunity, while others produce immunosuppressive
effects (Agostinis et al, 2011; Mroz and Hamblin, 2011). The
underlying mechanism responsible for potentiation or suppression
is not yet known; however, it has been suggested that they may be
multifactorial and dependent on PDT treatment regimen, the area
treated and the photosensitiser used. In our case, we saw that Treg
reach a peak value between 0 and 4 days just in two animal groups:
PDT no cancer and PDT cancer. The same two groups reach the
peak of Treg at the same time points also in the LNs. We
hypothesise that this early immunosuppressive effect of PDT may
result from a strong inflammatory response induced by PDT at site of
the treatment. The host’s immune system might produce more Tregs
to limit the local acute inflammation. Obviously, after day 4 the
Table 1. P-values of Treg in spleen
Time points (days)
0 1 4 10 14
Naive — — — — —
A. PDT no cancer n.s. vs A4 — n.s. vs A10 — —
B. PDT cancer Po0.001 vs B4 Po0.01 vs B4
n.s. vs B10
Po0.001 vs D4
Po0.01 vs naive
n.s. vs B0
n.s. vs naive
n.s. vs naive
C. Sham PDT cancer — — — — Po0.001 vs B14
D. PDTþCY cancer n.s. vs D4 — n.s. vs naive n.s. vs naive n.s. vs D0
n.s. vs naive
E. CY cancer — — — Po0.001 vs E14 Po0.001 vs B14
Po0.001 vs naive
Abbreviations: CY¼cyclophosphamide; PDT¼photodynamic therapy; Treg¼T regulatory cells. —, comparison not applicable.
Table 2. P-values of Treg in lymph nodes
Time points (days)
0 1 4 10 14
Naive — — — — —
A. PDT no cancer Po0.01 vs A4 Po0.01 vs A4 — n.s. vs A1 —
B. PDT cancer Po0.05 vs B4 — Po0.001 vs D4
Po0.001 vs naive
n.s. vs B0
n.s. vs naive
n.s. vs naive
C. Sham PDT cancer — — — Po0.001 vs C0 Po0.001 vs B14
D. PDTþCY cancer n.s. vs D4 — n.s. vs naive n.s. vs naive
n.s. vs D0
n.s. vs naive
E. CY cancer — Po0.001 vs E14 — — Po0.01 vs E14
Po0.001 vs naive
Abbreviations: CY¼cyclophosphamide; PDT¼photodynamic therapy; Treg¼T regulatory cells. —, comparison not applicable.
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restored the normal immunological conditions. This may explain why
Treg was increased in the first days after PDT, even in the absence of
tumour and after 4 days decreased again to the ‘naı ¨ve’ level.
The administration of 50mgkg
 1 of CY led to a considerable
depletion of Treg in both spleen and LNs and nadir was reached at
2 days after CY administration (the time we selected to deliver
PDT). The reduction in the absolute number of Treg was more
remarkable in LNs than in spleen; the reason could be that while
LNs are more pure pools of T cells, the spleen is acting mainly as a
blood filter and contains a wider variety of different subsets of cells.
The literature suggest three possible mechanisms of selective
depletion of Treg exerted by low-dose CY: (i) inhibition of
proliferation of the more rapid proliferating Tregs as compared
with other classes of lymphocytes (Ercolini et al, 2005), (ii)
induction of apoptosis and functional inhibition of Tregs (Lutsiak
et al, 2005) and (iii) inhibition of inducible nitric oxide synthase
that controls the number of Tregs (Loeffler et al, 2005).
It remains to be fully elucidated how long the effect of low-dose
CY on Treg lasts for. Peng et al (2013) have recently found that a
single dose administration of CY leads to a reduction in the
number of Tregs in the tumour microenvironment in a transient
manner. Eight days after CY injection they observed comparable
levels of Tregs in mice treated with CY or untreated, suggesting
that a repopulation of Treg occurs some days after CY
administration. Here, we saw that after the initial depletion of
Treg, from day 3 onwards following CY administration the number
of Treg has steadily increased over time; however, this increase
coincided with progression of tumour and increase in tumour
volume. It was only when PDT was combined with 50mgkg
 1 of
CY, that the increase in Treg was not seen, either in spleen or in
LNs, at any time point after the therapy. This observation
correlated with the PDT-mediated regression of the tumour and
decrease in tumour volume.
To further investigate the relationship of Treg and tumour
microenvironment in the context of PDT and CY therapy, we
measured the levels of TGF-b in the serum of the mice at different
time points after PDT. The TGF-b signalling has a complex role in
carcinogenesis, having both tumour suppressor and oncogenic
activities. It has been shown that TGF-b exerts tumour suppressor
effects in normal epithelial cells and in early stage of tumour
progression by inducing cell-cycle arrest, senescence and apoptosis.
Conversely, during the progression of cancer the anti-proliferative
effects of TGF-b are selectively lost and TGF-b induces many
activities leading to growth, invasion and metastasis of cancer cells
(Nagaraj and Datta, 2010). Cancer cells often escape from the
growth inhibitory function of TGF-b by mutational inactivation or
dysregulated expression of components in its signalling. It also
known that increased levels of TGF-b lead to adverse effects on
anti-tumour-immunity in multiple ways: inhibiting the prolifera-
tion and differentiation of T lymphocytes, natural killer cells,
neutrophils, macrophages and B cells (Letterio and Roberts, 1998)
and promoting the function of Tregs (Wan and Flavell, 2008).
Moreover, Tregs mediate their suppressive activity by producing
TGF-b themselves. We expected that any effect induced by PDT
and/or CY on the function and level of Tregs could be reflected
also in the level of TGF-b in the serum. However, it is necessary to
consider that also other cell types are capable of secreting TGF-b,
such as cancer cells (Elliott and Blobe, 2005), macrophages
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Figure 4. Detection of TGF-b. (A) RT–PCR analysis of TGF-b expression
in CT26 cells. (B) Mean levels of TGF-b cytokine measured in the serum
from mice at different time points after PDT, PDTþCY, or surgically
operated, as well as in control naı ¨ve mice. Statistical comparisons are
shown in Table 3 and significance was determined by one-way ANOVA
and Tukey post hoc correction.
Table 3. P-values of TGF-b
Time points (days)
01 4 1 01 4
Naive — — — — —
A. PDT
cancer
Po0.01 vs A1
Po0.001 vs
naive
— Po0.01 vs
A0
— Po0.05 vs A0
B. PDTþCY
cancer
Po0.01 vs B1
Po0.001 vs
naive
— n.s. vs A4
Po0.001
vs B0
— n.s. vs A14
Po0.001 vs
B14
C. Surgery
cancer
Po0.001 vs
naive
— Po0.01 vs
C0
— Po0.001 vs C0
n.s. vs naive
Abbreviations: CY¼cyclophosphamide; PDT¼photodynamic therapy; Treg¼T regulatory
cells. —, comparison not applicable.
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Figure 5. Tumour rechallenge of cured mice. Kaplan–Meier survival
curves of the % of mice surviving after rechallenge with CT26 in the
groups: naı ¨ve; naı ¨veþCY; CT26 cured; CT26 curedþCY. The median
survival time of PDTþCY rechallenged mice was 18 days vs 25 days for
naı ¨ve mice (P¼0.0009).
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therefore, the kinetics of TGF-b may not exactly reflect the kinetics
of Treg numbers.
We have confirmed that indeed the CT26 cancer cells do
express TGF-b (Figure 4A), a characteristic that may strongly
contribute to the development of immunosuppressive microenvir-
onment of this tumour. The fact that CT26 tumours are a
significant source of TGF-b in tumour-bearing mice may explain
why the TGF-b and Treg levels continued to increase unabated
with tumour progression and returned to ‘naı ¨ve’ levels when the
tumour was removed by surgery or PDT. Photodynamic therapy
and PDTþCY had similar impacts on TGF-b; however, the two
effects were not identical. Photodynamic therapyþCY caused a
more pronounced reduction in TGF-b compared with PDT alone,
decreasing the level to a range comparable to naı ¨ve mice. When
PDT was applied alone, we observed a reduction in TFG-b,
however, it remained significantly higher than in naı ¨ve mice.
In CT26 tumour model, the combined PDTþCY treatment led
to long-term tumour regression, however, none of the mice treated
by combination therapy rejected the subsequent tumour rechal-
lenge. It was only when we administered a second dose of CY
before rechallenge that 65% of mice in long-term remission after
PDTþCY treatment successfully rejected the rechallenge. We
attribute this effect to the fact that CT26 cells express a tumour
rejection antigen gp70 (Figure 1B) that appears to behave like a
shared auto-antigen. It appears that Treg can suppress the
development of anti-gp70 immunity and/or reactivation of anti-
gp 70 memory immunity; however, this effect can be uncovered
when Treg is depleted before PDT and again before rechallenge.
This observation may have far-reaching clinical implication as it
suggests that in patients treated with PDT there may be developing
anti-tumour immunity that could be uncovered at the time of
relapse by appropriately designed anti-Treg therapy. If PDT was
ever combined with low-dose CY in patients, then it may be
possible to use a metronomic CY regimen (Ge et al, 2012) rather
than a bolus administration to extend the length of time that Tregs
were controlled until the possibility of tumour recurrence was no
longer a real threat. In conclusion, the presented results further
enrich our understanding of the effects of the role of Treg in PDT-
mediated anti-tumour immune response. Further studies, however,
are certainly necessary to fully understand the complicated
interaction between PDT, Treg, immunosuppressive microenvir-
onment of the tumour and the role of different types of tumour
antigens to better design and exploit PDT-based immunotherapy
to improve patient outcome.
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